theragnostics

theragnostics

(ther″ăg-nos′tiks) [ therapy + diagnostics]
The use of molecular diagnostic techniques, e.g. the identification of the enzymes one person makes that another does not, to guide treatment decisions such as the choice of drugs that will be optimally metabolized by a particular patient.
References in periodicals archive ?
Radiopharmaceutical company Theragnostics Limited revealed on Friday the election of Nick Stevens as its executive chairman.
Partners: King's College London, University of Edinburgh, AstraZeneca, Birmingham Children's Hospital NHS FT, Briggs of Burton PLC, Bristol-Myers Squibb Pharm Research UK, Campden BRI, City University of Hong Kong, GE Healthcare, Guys Kings and St Thomas, Imerys Minerals Ltd, Mondelez UK R&D Ltd, Siemens, Stanford University Medical School, Theragnostics Ltd, Unilever (UK), University of British Columbia, University of Cape Town, University of Tennessee, Knoxville, University of Wisconsin Madison
Novartis also strengthened its cancer product portfolio during the year when it paid nearly $4 billion for Advanced Accelerator Applications (AAA), a nuclear medicine theragnostics company.
In the past few months several other key events have confirmed the trend of an increasing interest for the nuclear medicine market, such as Jubilant Pharma acquiring Triad Isotopes, Sofie Biosciences purchasing Zevacor Pharma, Theragnostics Ltd.
Jin, "Magnetic nanoparticles for theragnostics," Advanced Drug Delivery Reviews, vol.
MRI/MRS is also a promising molecular imaging method for cancer theragnostics [23,24].
The application of mass-spectrometry-based protein biomarker discovery to theragnostics. Br.
For now, though, they are being used as "theragnostics"--that is, tests that guide decisions about treatment.
Jin, Magnetic nanoparticles for theragnostics, Adv Drug Deliv Rev, 61(6):467-77 (2009).
The effort to combine new biomarkers with complementary therapy has also led to the concept of theragnostics (a portmanteau of therapeutics and diagnostics).
Theragnostics Limited, a clinical stage company, has named Nick Stevens as its new executive chairman, it was reported on Friday.
Laboratory medicine is evolving as a whole, facing new challenges represented by translation of techniques developed for basic research (e.g., genomics, proteomics, theragnostics) in the routine of most clinical laboratories.